Form 4: Cara Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher Posner, CEO of Cara Therapeutics, sold 5,834 shares of common stock on February 29, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- Christopher Posner, the President and CEO of Cara Therapeutics, Inc., reported a transaction involving the sale of company stock.
- On February 29, 2024, Posner sold 5,834 shares of common stock at a price of $0.89 per share.
- The sale was executed under a pre-arranged 'sell to cover' arrangement adopted on November 2, 2022, to satisfy tax withholding obligations triggered by the vesting of restricted stock units.
- Following the transaction, Posner directly owns 180,521 shares of Cara Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is related to tax obligations and doesn't necessarily reflect a change in the executive's view of the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction appears to be related to tax obligations and not necessarily indicative of a change in the executive's outlook on the company.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 2022-11-02 | Date the reporting person adopted the 'sell to cover' arrangement. |
| 2024-02-29 | Date of the stock sale transaction. |
| 2024-03-04 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.